

# Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

Cissy Kityo,<sup>1,2</sup> Caitlyn McCarthy,<sup>2,3</sup> Serena P. Koenig,<sup>3,4</sup> Michael D. Hughes,<sup>2</sup> Carole L. Wallis,<sup>4</sup> Isaac Tsikhutsu,<sup>5</sup> Cornelius Munyanga,<sup>6</sup> Noluthando Mwelase,<sup>7</sup> Marije Van Schalkwyk,<sup>8,9</sup> Jean Bernard Marc,<sup>3</sup> Kelvin Mponda,<sup>9</sup> Rodney Dawson,<sup>10</sup> Fatma F. Some,<sup>11</sup> Lerato Mohapi,<sup>12</sup> Yvetot Joseph,<sup>13</sup> Urvi M. Parikh,<sup>14</sup> N. Sarita Shah,<sup>15</sup> Yukari C. Manabe,<sup>16,17</sup> Catherine Godfrey,<sup>17</sup> Elizabeth Woolley,<sup>18</sup> John W. Mellors,<sup>14</sup> and Charles Flexner<sup>16</sup>, ACTG A5381/Hakim Study Team

<sup>1</sup>Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda, <sup>2</sup>Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA, <sup>3</sup>Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti, <sup>4</sup>Innovative Clinical Laboratories, Johannesburg, South Africa, <sup>5</sup>Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho, Kenya, <sup>6</sup>Malawi Clinical Research Site (CRS), Lilongwe, Malawi, <sup>7</sup>University of the Witwatersrand Helen Joseph (WITS HJH) CRS, Johannesburg, South Africa, <sup>8</sup>Family Centre for Research with Ubuntu (FAMCRU) CRS, Stellenbosch University, Cape Town, South Africa, <sup>9</sup>Blantyre Clinical Research Site, Johns Hopkins Research Project, Blantyre, Malawi, <sup>10</sup>University of Cape Town Lung Institute, Cape Town, South Africa, <sup>11</sup>Moi University Clinical Research Center (MUCRC) CRS, Eldoret, Kenya, <sup>12</sup>Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa, <sup>13</sup>GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO-IMIS), Port-au-Prince, Haiti, <sup>14</sup>University of Pittsburgh Department of Medicine, Division of Infectious Diseases, Pittsburgh, Pennsylvania, USA, <sup>15</sup>Emory Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, <sup>16</sup>The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, <sup>17</sup>Walter Reed Army Institute of Research, Department of Defense, Kampala, Uganda, and <sup>18</sup>DLH Corporation, Silver Spring, Maryland, USA

**Background.** Tenofovir/lamivudine/dolutegravir (TLD) is widely prescribed worldwide. We report virologic and resistance outcomes for patients initiating or switching to TLD.

**Methods.** A prospective observational study was performed at 13 AIDS Clinical Trials Group sites in 6 President's Emergency Plan for AIDS Relief-supported countries coincident with TLD rollout. This report includes results from 2 groups: group 1 (Gp1) were virally suppressed on nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) and group 2 (Gp2) were ART-naïve at TLD initiation. The primary objective was to estimate the proportions of participants with HIV-1 RNA  $\leq 1000$  copies/mL and frequency of dolutegravir resistance mutations 6 months after TLD initiation.

**Results.** From October 2019 through July 2022, we enrolled 425 participants in Gp1 and 179 in Gp2. Two in Gp1 (0.5%) and 3 in Gp2 (1.7%) discontinued TLD by 6 months due to adverse events considered related to TLD ( $n = 4$ ) and participant decision ( $n = 1$ ). Ninety-three percent of participants in Gp1 and 92% in Gp2 who were still on TLD had a 6-month plasma HIV-1 RNA. Plasma HIV-1 RNA  $\leq 1000$ ,  $\leq 200$ , and  $< 50$  copies/mL was achieved in 99%, 98%, and 96% in Gp1 and in 90%, 87%, and 85% in Gp2, respectively. A new integrase mutation (T97A/T) was observed in 1 participant in Gp1 and none in Gp2.

**Conclusions.** TLD was well tolerated and achieved or maintained viral suppression ( $\leq 1000$  copies/mL) in 90% of ART-naïve and 99% of participants with preswitch viral suppression. An emerging integrase strand transfer inhibitor mutation of uncertain significance was detected in only 1 participant. These data support early tolerability, virologic efficacy, and rare integrase strand transfer inhibitor resistance emergence with TLD transition or initiation in programmatic settings.

**Keywords.** Africa region; ART; LMIC; observational prospective study; viral suppression.

Dolutegravir-based antiretroviral therapy (ART) regimens have fewer drug–drug interactions, improved tolerability and greater potency, compared with previously recommended

regimens [1–8] and a high genetic barrier to resistance [9, 10]. Systematic reviews have demonstrated the comparative efficacy and tolerability of integrase strand transfer inhibitors (INSTIs), particularly dolutegravir (DTG), in achieving and maintaining viral load (VL) suppression up to 96 weeks without treatment-emergent resistance [11–13]. In addition, epidemiological modeling using African data has shown that scaling up DTG-based regimens could curb nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistance, reducing pretreatment drug resistance from about 52% (without DTG) to 10% (with universal DTG use) by 2040 [14].

The fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and DTG (TLD), is an optimal regimen for use in

Received 13 March 2025; editorial decision 28 April 2025; accepted 29 April 2025; published online 2 May 2025

Correspondence: Cissy Kityo, MBChB, PhD, Joint Clinical Research Centre, Plot 101 Lubowa, Kampala, Uganda (ckityo@jrcr.org.ug).

Open Forum Infectious Diseases®

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

<https://doi.org/10.1093/ofid/ofaf270>

low- and middle-income countries. The efficacy, cost, and favorable resistance characteristics have led to changes in the World Health Organization [15, 16] and the President's Emergency Plan for AIDS Relief (PEPFAR) [17] guidelines for the use of ART for persons with HIV (PWH) to INSTI-based regimens for treatment-naïve and treatment-experienced patients, especially in settings where resistance testing prior to ART initiation may not be feasible [15, 17, 18]. These guidelines, together with licensing and pricing agreements, have further catalyzed the global roll-out and access to generic DTG-based therapy, especially for low- and middle-income countries, where about 100 countries have implemented this transition.

Before the start of this study, there was a paucity of data on the risks, benefits, and emergence of DTG resistance in TLD rollout programs where viral load measurement does not always happen expeditiously and drug resistance testing is not widely used to guide ART management [17]. To address this gap, the Advancing Clinical Therapeutics Globally (ACTG) protocol A5381 (The Hakim Study) was designed to systematically track clinical and virologic outcomes among PWH who were initiating or transitioning to TLD while receiving care through a PEPFAR-supported program.

## METHODS

### Study Design and Participants

The Hakim Study was a prospective, longitudinal, observational cohort study to assess the therapeutic efficacy and emergence of HIV drug resistance following initiation or switch to TLD [19]. The primary objective was to estimate, 6 months after initiation of TLD, the proportion of participants with HIV-1 RNA  $\leq 1000$  copies/mL, and the proportion with new DTG resistance mutations. Group 1 (Gp1) includes participants on NNRTI-based ART for at least 6 months with HIV-1 RNA  $\leq 1000$  copies/mL before switch to TLD and group 2 (Gp2) includes participants initiating ART with TLD.

Participants were recruited and followed at 13 PEPFAR-supported clinical sites in 6 countries (South Africa, Malawi, Zimbabwe, Uganda, Kenya, and Haiti). To be eligible for participation, participants needed to be  $\geq 10$  years old with documented HIV-1 and receiving care at a PEPFAR-supported site. Additionally, participants enrolled into Gp1 had to have been taking NNRTI-containing first-line ART for at least 6 consecutive months prior to study entry with HIV-1 RNA  $\leq 1000$  copies/mL before switch to TLD. Participants in group 2 were expected to be ART-naïve (although women who received ART only during pregnancy and/or breastfeeding for prevention of mother-to-child transmission, but who had not taken any ART for at least 6 calendar months immediately prior to study entry, were allowed).

### Ethical Considerations and Patient Consent Statement

The trial was approved by local ethics committees and national regulatory agencies in the respective countries. All participants provided written informed consent or assent and parental/guardian informed consent if they were younger than age 18 years.

### Procedures

To the extent practically possible, all individuals on NNRTI-based ART or starting TLD at selected sites were approached for screening and enrollment on the study after signing informed consent. Enrolled participants were managed according to local standards of care, and preferably in accordance with current World Health Organization Guidelines for HIV treatment and monitoring [15]. Eligible participants initiated or switched to TLD provided by a PEPFAR-supported program within 7 days after enrollment.

Visits took place at study entry and at months 3 and 6. Targeted clinical events (including AIDS-defining conditions, fractures, coronary heart disease, cancer, death, depression, diabetes, immune reconstitution inflammatory syndrome, suicidal ideation, suicide attempt, tuberculosis, and HIV-associated nephropathy) and adverse events leading to TLD discontinuation were assessed at each visit and graded according to the Division of AIDS toxicity grading table [20]. Plasma HIV-1 RNA was measured at entry and 6 months.

For participants with HIV-1 RNA  $> 1000$  at 6 months, genotypic resistance testing was performed on a 6-month plasma sample, and, in Gp2, on a sample obtained at study entry if the participant also had HIV-1 RNA  $> 1000$  copies/mL at that time (for those with HIV-1 RNA  $\leq 1000$  copies/mL at entry, no resistance testing was performed on the entry sample and any mutations identified during follow-up were considered to be new). Resistance testing was performed in College of American Pathologists-accredited specialty laboratories (BARC-SA and Lancet Laboratories, and Pittsburgh Virology Specialty Laboratory). Drug resistance mutations were identified using the Stanford Algorithm (version 8.8).

Enrollment occurred from October 2019 to July 2022 but was paused from March to July 2020 because of the COVID-19 pandemic. During the pandemic, remote data collection was allowed if a participant was unable to attend a scheduled visit or a site was unable to conduct nonessential visits in the clinic.

## OUTCOMES AND STATISTICAL ANALYSES

### Primary Outcome Measures

The primary virologic outcome was suppression of plasma HIV-1 RNA to  $\leq 1000$  copies/mL at 6 months after starting TLD. The proportion of study participants with HIV-1 RNA  $\leq 1000$  copies/mL was estimated, together with the associated 2-sided exact 95% CI calculated based on the binomial distribution.

The primary resistance outcome was virologic failure (HIV-1 RNA >1000 copies/mL) with new DTG-associated resistance mutations at 6 months after starting TLD. New DTG resistance mutations were defined as those detected at the time of the failing measurement that were not detected at the time of TLD initiation. Changes in mixture mutations were not counted as new. Within each group, the proportion with HIV-1 RNA >1000 copies/mL and new DTG resistance mutations was estimated, together with the associated 2-sided exact 95% CI.

For the primary outcome, the analysis population included all participants who remained on TLD and received a 6-month HIV-1 RNA measurement. Subgroup comparisons by sex at birth were descriptive for the primary virologic outcome, showing the number and percentage of participants having the outcome of interest by sex at birth within each study group. Predictors of viral suppression at 6 months were analyzed using logistic regression, using the following prespecified variables in univariable models: sex at birth, age at TLD start, baseline CD4 count, and baseline log<sub>10</sub> HIV-1 RNA.

### Other Outcome Measures

Secondary and exploratory outcomes included suppression of plasma HIV-1 RNA to ≤200 and <50 copies/mL at 6 months, frequency of adverse events leading to TLD discontinuation, and frequency of clinical events relevant to TLD.


### Sample Size

Sample sizes of 360 participants in Gp1 and 180 participants in Gp2 were chosen to address the primary objective of estimating the virologic success rate at 6 months after starting TLD among those still on TLD at 6 months. For Gp1, the width of a 95% CI would be approximately ±3.1% if the success rate was 90% as hypothesized. For Gp2, the width of a 95% CI would be approximately ±5.2% if the success rate was 85% as hypothesized.

## RESULTS

From October 2019 to July 2022, 425 participants were enrolled into Gp1 and 181 participants were enrolled into Gp2 (Figure 1). Two participants in Gp2 did not start TLD, giving an analysis population of 179 participants in Gp2. Participant characteristics are provided for each cohort in Table 1.

Two participants (0.5%) in Gp1 and 3 (1.7%) in Gp2 discontinued TLD by 6 months (Figure 1). Two (0.5%) participants in Gp1 and 12 participants (6.7%) in Gp2 experienced at least 1 targeted clinical event through to 6 months. Both participants in Gp1 had diabetes. In Gp2, 7 participants (3.9%) had tuberculosis, 4 (2.2%) had AIDS-defining conditions, 3 (1.7%) died (1 from TB, 1 from acute renal failure, and 1 unknown cause), and 1 (0.6%) each had cancer and immune reconstitution inflammatory syndrome.



**Figure 1.** STROBE diagram.

**Table 1. Baseline Characteristics**

|                                    |                      | Group 1b<br>(N = 425) | Group 4<br>(N = 179) |
|------------------------------------|----------------------|-----------------------|----------------------|
| Sex                                | Female               | 339 (80%)             | 75 (42%)             |
| Gender identity                    | Cisgender            | 425 (100%)            | 178 (99%)            |
|                                    | Transgender spectrum | 0 (0%)                | 1 (1%)               |
| Age (y)                            | Median (IQR)         | 41 (33, 47)           | 35 (28, 42)          |
|                                    | Min, Max             | 10, 74                | 18, 61               |
| Country                            | Haiti                | 7 (2%)                | 47 (26%)             |
|                                    | Kenya                | 123 (29%)             | 29 (16%)             |
|                                    | Malawi               | 40 (9%)               | 71 (40%)             |
|                                    | South Africa         | 140 (33%)             | 4 (2%)               |
|                                    | Uganda               | 57 (13%)              | 25 (14%)             |
|                                    | Zimbabwe             | 58 (14%)              | 3 (2%)               |
| HIV-1 RNA (copies/mL)              | <50                  | 402 (95%)             | 25 (14%)             |
|                                    | 50–200               | 13 (3%)               | 1 (1%)               |
|                                    | 201–1000             | 10 (2%)               | 10 (6%)              |
|                                    | 1001–10 000          | 0 (0%)                | 30 (17%)             |
|                                    | 10 001–100 000       | 0 (0%)                | 65 (36%)             |
|                                    | >100 000             | 0 (0%)                | 48 (27%)             |
| CD4 count (cells/mm <sup>3</sup> ) | Median (IQR)         | 676 (477, 893)        | 302 (165, 517)       |
|                                    | Min, Max             | 56, 2277              | 1, 1574              |
|                                    | # missing            | 10                    | 10                   |

In Group 4, the median HIV-1 RNA was 4.4 log<sub>10</sub> copies/mL (IQR: 3.5, 5.1).

Abbreviation: IQR, interquartile range.

Among participants followed on TLD through 6 months, 384 (93.2%) in Gp1 and 151 (91.5%) in Gp2 had a 6-month HIV-1 RNA result and were included in the analysis of the primary outcome measure. Twenty-two participants (5.3%) in Gp1 and 9 participants (5.5%) in Gp2 did not have a result because they had a remote visit during the COVID-19 pandemic where a sample could not be obtained. For the remaining 11 participants (6 [1.5%] in Gp1 and 5 [3.0%] in Gp2) with no result, there was contact after 6 months but no physical study visit at 6 months because of missed or remote visits (considered unrelated to the pandemic).

The proportion of participants with HIV-1 RNA ≤1000 copies/mL was 99% (n = 380) in Gp1 and 90% (n = 136) in Gp2. The exploratory virologic outcomes using thresholds of 200 and 50 copies/mL were achieved in 98% and 96% of participants in Gp1, respectively, and in 87% and 85% of participants in Gp2 (Table 2).

All participants who had a missing VL because of virtual visits during the COVID-19 pandemic were from 1 site. A sensitivity analysis that excluded all participants at this site showed similar results (99% in Gp1 and 91% in Gp2 with HIV-1 RNA ≤1000 copies/mL) to the primary analysis. In additional sensitivity analyses, the proportion of participants in Gp1 with HIV-1 RNA ≤1000 copies/mL was 99% (exact 95% CI, 98–100) under the best-case scenario (missing results were imputed as HIV-1 RNA ≤1000 copies/mL) and 95% (exact 95% CI, 92–97) under the worst-case scenario (missing results

imputed as HIV-1 RNA >1000 copies/mL). In Gp2, the proportion was 91% (exact 95% CI, 86–95) under the best-case scenario and 83% (exact 95% CI, 76–88) under the worst-case scenario. Note that among the 28 participants in Gp1 and 12 in Gp2 who had no 6-month VL but who were seen in clinic thereafter, all had HIV-1 RNA ≤1000 copies/mL when seen next in-clinic (and all except 1 were <50 copies/mL), so more consistent with the best-case rather than worst-case scenario.

In Grp 1, the proportion of participants with HIV-1 RNA ≤1000 copies/mL at 6 months was 99% in females and 100% in males; in Grp 2, this proportion was 95% for females and 86% for males. Analyses of predictors of viral suppression were not performed in Gp1 because of very high suppression rates. In Gp2, higher age at TLD initiation was associated with greater odds of viral suppression (odds ratio [OR] per 10 years, 4.59; 95% CI, 1.98–10.7) and higher quantitative baseline HIV-1 RNA was associated with lower odds (OR per 1 log<sub>10</sub> copies/mL higher: 0.56; 95% CI, 0.32–1.00) of HIV-1 RNA ≤1000 copies/mL at 6 months. Sex at birth was not significantly associated with viral suppression (OR, 3.35; 95% CI, 0.90–12.41; *P* = .070).

One of 4 participants in Gp1 who had HIV-1 RNA >1000 copies/mL at 6 months had a mutation (T97A/T) detected, which was presumed to be new, and that was possibly selected by DTG; it is noteworthy that this participant had HIV-1 RNA <40 copies/mL at study entry. The proportion of participants with new resistance in Gp1 was therefore 0.3% (1/383; exact 95% CI, 0–1.5). No new DTG resistance mutations were

**Table 2. Proportion of Participants on TLD at 6 Months With HIV-1 RNA Suppressed to 3 Thresholds:  $\leq 1000$ ,  $\leq 200$ , and  $<50$  Copies/mL**

|                                 | Group 1b<br>(N = 425)              |                  | Group 4<br>(N = 179)               |                  |
|---------------------------------|------------------------------------|------------------|------------------------------------|------------------|
|                                 | N/total on TLD<br>with measurement | % (exact 95% CI) | N/total on TLD<br>with measurement | % (exact 95% CI) |
| Primary virologic outcome:      | ...                                | ...              | ...                                | ...              |
| HIV-1 RNA $\leq 1000$ copies/mL | 380/384                            | 99.0 (97.4–99.7) | 136/151                            | 90.1 (84.1–94.3) |
| Exploratory virologic outcomes: | ...                                | ...              | ...                                | ...              |
| HIV-1 RNA $\leq 200$ copies/mL  | 378/384                            | 98.4 (96.6–99.4) | 132/151                            | 87.4 (81.0–92.3) |
| HIV-1 RNA $<50$ copies/mL       | 369/384                            | 96.1 (93.6–97.8) | 128/151                            | 84.8 (78.0–90.1) |

The total on TLD with measurement was noticeably impacted by the number of participants with missed clinic visits and with virtual visits due to the COVID-19 pandemic at 6 m (see Figure 1).  
Abbreviation: TLD, tenofovir/lamivudine/dolutegravir.

observed among the 15 participants in Gp2 with HIV-1 RNA  $>1000$  copies/mL at 6 months. The proportion of participants with new resistance in Gp4 was therefore 0% (0/151; exact 95% CI, 0–2.4). Four participants in Gp2 who had DTG resistance mutations (L74IMV, T97AT, G163 K, and E157Q) at 6 months showed similar patterns of resistance at study entry.

## DISCUSSION

We report primary results from an observational cohort of PWH who were receiving ART through the PEPFAR program in Africa and Haiti. This is one of the few studies providing data on early therapeutic efficacy and emergence of HIV drug resistance after switch to TLD for virologically suppressed participants taking NNRTI-based ART and initiation of TLD for ART-naïve participants from implementation program settings outside of a clinical trial context. We found that in an already well-suppressed cohort on NNRTI-based first-line ART (Gp1), 99% maintained plasma HIV-1 RNA suppression ( $\leq 1000$  copies/mL) at 6 months after switching to TLD. In a parallel cohort of ART-naïve individuals (Gp2), 90% achieved this outcome. The lower rate of viral suppression among ART-naïve individuals is not unexpected: those starting ART may have yet to fully suppress because of shorter duration of ART, or they may be less adherent to a treatment regimen than individuals who have already achieved suppression on a first-line regimen. Rates of viral suppression were slightly lower using thresholds of  $\leq 200$  copies/mL and  $<50$  copies/mL. Among participants with viral load  $>1000$  copies/mL at 6 months, development of new DTG resistance at 6 months was low at 0.3% for those switching from NNRTI-based therapy and 0% for those who were ART-naïve.

These results are consistent with the findings of randomized clinical trials that evaluated DTG in switch and ART initiation studies [4, 5, 21, 22]. It is highly encouraging that our results are also consistent with the earlier findings from observational studies in sub-Saharan Africa. A facility-based survey conducted at 2 ART reference treatment centers in Cameroon showed an overall viral suppression rate ( $<1000$  copies/mL) of 96%

after 14 months of therapy in individuals either initiating or transitioning to TLD [23]. Another cohort in Lesotho (DO-REAL study) reported on PWH transitioning to a DTG-containing regimen from a NNRTI-based regimen with excellent virologic outcomes (98% had viral load  $<1000$  copies/mL at 16 weeks, with no DTG resistance observed) [24]. In a large cohort from Malawi, 99% of patients with preswitch suppression on first-line ART maintained viral suppression after switching to TLD [25]. In the AFRICOS study, an observational cohort including 12 PEPFAR-supported clinical sites in Nigeria, Kenya, Uganda, and Tanzania, 94% of participants achieved viral suppression ( $<1000$  copies/mL) after switching to TLD [26–28], and 84% of participants maintained a viral load of  $<50$  copies/mL [27].

We noted an unexpectedly high proportion (20%) of participants in Gp2 with HIV-1 RNA  $<1000$  copies/mL before starting TLD, including 14% with HIV-1 RNA  $<50$  copies/mL. This level of HIV-1 RNA suppression could be due to spontaneous HIV-1 control, or from undisclosed use of ART, which has been reported previously, and which may explain the small number of DTG resistance mutations which were present at study entry [29].

Among ART-naïve PWH initiating TLD, there was no development of new resistance to DTG through 6 months, a finding similar to that in pivotal phase 3 studies [1, 4–7, 9, 30]. Four participants had DTG resistance mutations (L74IMV, T97AT, G163K, and I157Q) at 6 months, but had similar patterns of resistance at study entry. Among participants switching from NNRTI-based regimens, only 1 new mutation (T97A/T) was observed. None of these mutations decrease susceptibility to dolutegravir, unless in combination with other INSTI-resistance mutations [31, 32] (35). These results are similar to other studies which reported no or low rates of DTG resistance among patients initiating TLD or switching from suppressive regimens [24, 25, 33]. This finding is particularly salient for implementers and policymakers as they consider scaling up resistance testing versus intensifying efforts to support differentiated adherence counseling. These results support the

virological effectiveness of pragmatic transitioning as observed in this study.

This study was conducted at PEPFAR sites that are affiliated with ACTG sites. This may potentially limit the generalizability of our findings. In addition, the follow-up period was relatively short, and a small number of participants discontinued the study or lacked viral load results.

## CONCLUSION

This study demonstrates that TLD is associated with high rates of tolerability and viral suppression in individuals who are ART-naïve or suppressed on first-line NNTRI-based regimens, without emergence of clinically significant DTG resistance mutations after 6 months of treatment.

## Notes

**Acknowledgments.** Presented in part at the 29th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February 12–16, 2022. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Health and Human Services, or the Department of State.

The authors thank the study participants and A5381/Hakim Study team members, including Marie Jude Jean Louis, Daphie Jean François, Vanessa Rouzier, and Damocles Patrice Severe (GHESKIO Institute of Infectious Diseases and Reproductive Health); Mina C. Hosseinipour, (Malawi Clinical Research Site), Elliot Raizes, (US Centers for Disease Control and Prevention); Deborah Langat (Kenya Medical Research Institute/Walter Reed Project Clinical Research Center [KEMRI/WRP] CRS); Mohammed Rassool, Vuyokazi S. Jezile and Thando Mwelase (University of the Witwatersrand Clinical HIV Research Unit, Helen Joseph Hospital); Abraham Siika and Viola Kirui (Moi University CRS); Rosie Mngqibisa, Penelope Madlala, and Petronella Casey (Durban Clinical Research Site); Wadzanai Samaneka and Yeukai Musodza (Milton Park Clinical Research Site); Nadia Magengo and Suri Moonsamy (Soweto Clinical Research Site); Mulinda Nyirenda (Blantyre CRS); Francis Kanyike (Joint Clinical Research Centre CRS); Lynne Cornelissen and Lindee Ganger (FAMCRU CRS).

**Author Contributions.** C.K., C.F., J.W.M., C.G., Y.C.M., U.M.P., M.D.H., C.L.W., S.P.K., N.S.S., and E.W. designed the study. C.K., C.F., J.W.M., and E.W. coordinated the study. I.T., C.M., N.M., M.V.S., J.W.M., K.M., R.D., F.F.S., L.M., and O.Y. enrolled participants in the study and followed them up. M.D.H. and C.M. accessed and verified the data and did the statistical analysis. All authors interpreted data, provided input into the report, and approved the final version of the report.

**Disclaimer.** C.G. wrote this in her capacity as a US government employee; the views expressed are her own and should not be construed to represent the positions of the Department of Defense, the Department of State, the United States Agency for International Development, or the Department of Health and Human Services.

**Data Availability Statement.** Anonymized individual participant data and study documents can be requested from the corresponding author and will be made available from 12 months after publication of this paper, subject to approval of the Study Protocol Team and ACTG.

**Financial support.** This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI06866, and UM1 AI106701. Participating Advancing Clinical Therapeutics Globally (ACTG) sites were supported under the following grant numbers: UM1AI69518 (Blantyre CRS), UM1AI069521 (FAMCRU CRS), UM1AI69421 (GHESKIO-IMIS CRS), UM1AI69501 (JCRC/Kampala CRS), UM1AI108568 (KEMRI/WRP CRS), UM1AI69421 (GHESKIO-INLR CRS), UM1AI69423 (Malawi CRS), UM1AI69436 (Milton Park CRS),

UM1AI108568 (MUCRC CRS), UM1AI69453 (Soweto CRS), UM1AI69519 (UCTLI CRS), UM1AI69463 (Wits HJH CRS).

**Potential Conflicts of Interest.** C.F. has been a paid consultant in the past 3 years to Gilead Sciences, Merck, and ViiV Healthcare. Other authors do not have conflict of interest with regards to this work.

## References

1. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet* **2014**; *383*: 2222–31.
2. Nickel K, Halfpenny NJA, Snedecor SJ, Puneekar YS. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. *BMC Infect Dis* **2021**; *21*:222.
3. Patel DA, Snedecor SJ, Tang WY, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naïve HIV-1-infected patients: a systematic review and network meta-analysis. *PLoS One* **2014**; *9*:e105653.
4. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med* **2013**; *369*:1807–18.
5. Calmy A, Sanchez TT, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open-label, phase 3 non-inferiority trial in Cameroon. *Lancet HIV* **2020**; *7*:e677–87.
6. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. *Lancet HIV* **2015**; *2*: e127–36.
7. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* **2013**; *13*:927–35.
8. Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naïve adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. *J Acquir Immune Defic Syndr* **2020**; *83*:310–8.
9. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. *Lancet* **2013**; *382*:700–8.
10. van Wyk J, Ajana F, Bishop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. *Clin Infect Dis* **2020**; *71*:1920–9.
11. Kanter S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. *Lancet HIV* **2016**; *3*:e510–20.
12. Kanter S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. *EClinicalMedicine* **2020**; *28*:100573.
13. Snedecor SJ, Radford M, Kratochvil D, Grove R, Puneekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. *BMC Infect Dis* **2019**; *19*:484.
14. Hauser A, Kusejko K, Johnson LF, et al. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: a modeling study. *PLoS Med* **2020**; *17*: e1003397.
15. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, World Health Organization. **2021**.
16. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization, **2018**.
17. PEPFAR 2021 Country and Regional Operational Plan (COP/ROP) Guidance for all PEPFAR Countries. Available at: <https://www.state.gov/wpcontent/uploads/2021/02/PEPFAR-COP21-Guidance-Final.pdf>.
18. Vitoria M, Hill A, Ford N, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? *AIDS* **2018**; *32*:1551–61.

19. ClinicalTrials.gov. Available at: <https://www.clinicaltrials.gov/study/NCT04050449?term=A5381&rank=1>. Accessed 9 February 2025.
20. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1. July 2017. Available at: <https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables>.
21. Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. *Antivir Ther* **2017**; 22:295–305.
22. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV* **2020**; 7:e666–76.
23. Semengue ENJ, Fokam J, Etame N-K, et al. Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-line ART in Cameroon: an evidence of a successful transition model. *Viruses* **2022**; 15:18.
24. Brown JA, Nsakala BL, Mokhele K, et al. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study). *HIV Med* **2022**; 23:287–93.
25. Schramm B, Temfack E, Descamps D, et al. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. *Lancet HIV* **2022**; 9:e544–53.
26. Bahemana E, Esber A, Dear N, et al. Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African cohort study. *AIDS Res Ther* **2020**; 17:66–8.
27. Esber A, Dear N, Shah N, et al. Brief report: virologic impact of the dolutegravir transition: prospective results from the multinational African cohort study. *J Acquir Immune Defic Syndr* **2022**; 91:285.
28. Kiweewa F, Esber A, Musingye E, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African cohort study. *PLoS One* **2019**; 14:e0211344.
29. Benade M, Maskew M, Juntunen A, Flynn DB, Rosen S. Prior exposure to antiretroviral therapy among adult patients presenting for HIV treatment initiation or reinitiation in sub-Saharan Africa: a systematic review. *BMJ Open* **2023**; 13:e071283.
30. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med* **2019**; 381:803–15.
31. Stanford University. HIV Drug Resistance Database, Version 9.7. Available at: <https://hivdb.stanford.edu>.
32. Llacer Delicado T, Torrecilla E, Holguín Á. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naïve individuals. *J Antimicrob Chemother* **2016**; 71:362–6.
33. Tschumi N, Lukau B, Tlali K, et al. Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho. *Clin Infect Dis* **2024**; 79:1208–22.